1. Home
  2. CRDF

as 03-28-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Founded: 1999 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 288.7M IPO Year: N/A
Target Price: $12.00 AVG Volume (30 days): 1.1M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.95 EPS Growth: N/A
52 Week Low/High: $2.01 - $6.38 Next Earning Date: 05-01-2025
Revenue: $683,000 Revenue Growth: 39.96%
Revenue Growth (this year): -50.22% Revenue Growth (next year): -70.00%

CRDF Daily Stock ML Predictions

Share on Social Networks: